FDA Chronic kidney disease

Ozempic receives FDA nod for treating chronic kidney disease

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

CNBC on MSN · 2d

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

The Baltimore Sun · 16h

FDA approves Ozempic to help reduce risk of worsening chronic kidney disease

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of

Contract Pharma22h

FDA Approves Ozempic in Chronic Kidney Disease

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

Seeking Alpha1h

2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment

Currently, Rilparencel’s Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that’s suitable ...

14h

Q&A: How a scientist helped ban a chemical connected to Parkinson's disease

The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...

Renal & Urology News21h

KDIGO Issues New ADPKD Guideline

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results